Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals3.82%-0.88 ppManaged Health Care1.39%-0.68 ppBiotechnology1.79%-0.61 ppLife Sciences Tools & Services1.15%-0.49 ppHealth Care Equipment2.43%-0.46 ppHealth Care Services0.41%-0.28 ppHealth Care Distributors0.35%-0.06 ppHealth Care Facilities0.17%-0.04 ppHealth Care Technology0.03%+0.03 ppHealth Care Supplies0.13%-0.02 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.79%
Industry change · 12M
-0.61 pp
Biotechnology · contribution
-0.608 pp
Company participation
25%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Dec 2024 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Amgen → AMGN | United States | $140.1bn | 0.318% | -0.085 pp | -0.142 pp | -6.8% | No |
| AbbVie → ABBV | United States | $314.0bn | 0.712% | -0.100 pp | -0.104 pp | +18.9% | No |
| Regeneron Pharmaceuticals → REGN | United States | $66.9bn | 0.152% | -0.078 pp | -0.094 pp | -18.9% | No |
| Vertex Pharmaceuticals → VRTX | United States | $103.7bn | 0.235% | -0.044 pp | -0.078 pp | -1.0% | No |
| Moderna → MRNA | United States | $16.0bn | 0.036% | -0.024 pp | -0.077 pp | -58.2% | No |
| Biogen → BIIB | United States | $22.3bn | 0.051% | -0.015 pp | -0.061 pp | -40.9% | No |
| Gilead Sciences → GILD | United States | $115.1bn | 0.261% | +0.018 pp | -0.040 pp | +18.7% | Yes |
| Incyte → INCY | United States | $13.3bn | 0.030% | +0.001 pp | -0.012 pp | +10.0% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.